The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of cholesterolemia and body mass index on outcome of metastatic non small cell lung cancer treated with immunotherapy.
 
Giulia Galli
No Relationships to Disclose
 
Paola Corsetto
No Relationships to Disclose
 
Roberto Ferrara
No Relationships to Disclose
 
Arsela Prelaj
No Relationships to Disclose
 
Claudia Proto
No Relationships to Disclose
 
Diego Signorelli
No Relationships to Disclose
 
Nicoletta Zilembo
No Relationships to Disclose
 
Alessandro De Toma
No Relationships to Disclose
 
Filippo Pagani
No Relationships to Disclose
 
Giovanni Randon
No Relationships to Disclose
 
Monica Ganzinelli
No Relationships to Disclose
 
Antonio Sica
No Relationships to Disclose
 
Filippo G. De Braud
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Daiichi Sankyo; Dompè; Ignyta; Incyte; Novartis; Octimet; Pfizer; Pierre Fabre; Roche; SERVIER
Speakers' Bureau - Bristol-Myers Squibb; Menarini; MSD; Novartis; Pfizer; Roche
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Roche
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; GlaxoSmithKline; MSD Oncology; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche; Takeda; Tiziana Life Sciences
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; MSD Oncology; Roche; Takeda
Research Funding - AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Giuseppe Lo Russo
No Relationships to Disclose